A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab

Publisher： Karger

E-ISSN： 1662-6575|6|2|382-386

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.6, Iss.2, 2013-07, pp. : 382-386

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Panitumumab-Induced Interstitial Lung Disease in a Case of Metastatic Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 36, Iss. 4, 2013-03 ,pp. : 209-212

Karger

Access to resources Recommend Favorite

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

By Lawrence Donna   Maschio Michael   Leahy Kevin J.   Yunger Simon   Easaw Jacob C.   Weinstein Milton C.  

Journal of Medical Economics, Vol. 16, Iss. 12, 2013-12 ,pp. : 1387-1398

Informa Healthcare

Access to resources Recommend Favorite

The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 224-230

Karger

Access to resources Recommend Favorite

Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 185-191

Karger

Access to resources Recommend Favorite

Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801)

By  

Oncology, Vol. 87, Iss. 1, 2014-06 ,pp. : 7-20

Karger

Access to resources Recommend Favorite